Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.40 |
| ▸ | PYGM | P11217 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563352 | 0.80 | GAA (0.36) | PYGBPYGLPYGM | |
| SCHEMBL17460438 | 0.80 | GAA (0.36) | PYGBPYGLPYGM | |
| SCHEMBL2380968 | 0.80 | GAA (0.36) | PYGBPYGLPYGM | |
| SCHEMBL1843403 | 0.80 | GAA (0.36) | PYGBPYGLPYGM | |
| SCHEMBL30636631 | 0.78 | PYGB (0.36) | PYGBPYGLPYGM | |
| SCHEMBL14249031 | 0.77 | PYGB (0.37) | PYGBPYGLPYGMSLC5A2SLC5A1 | |
| SCHEMBL6839791 | 0.77 | PYGB (0.37) | PYGBPYGLPYGMSLC5A2SLC5A1 | |
| SCHEMBL27936287 | 0.76 | PYGB (0.44) | PYGBPYGLPYGM | |
| SCHEMBL16259329 | 0.74 | PYGB (0.41) | PYGBPYGLPYGMSLC5A2SLC5A1 | |
| SCHEMBL5703493 | 0.74 | PYGB (0.41) | PYGBPYGLPYGMSLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403378-B1 | Medium for detecting target microbes in a sample | IDEXX LAB INC (US) | 2008-02-27 | — | — | EP | claimed |
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | disclosed |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-02 | — | — | US | disclosed |
| US-7122359-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | disclosed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | PYGB 442/4885PYGL 455/4885PYGM 331/4885 |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | PNP, NUDT14, NUDT5 | PYGB 484/4885PYGL 532/4885PYGM 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.